- Home
- BRIA vs SER Comparison
BRIA vs SER Comparison
Compare BRIA & SER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRIA
- SER
- Stock Information
- Founded
- BRIA 2011
- SER 2017
- Country
- BRIA Singapore
- SER United States
- Employees
- BRIA N/A
- SER N/A
- Industry
- BRIA
- SER Biotechnology: Pharmaceutical Preparations
- Sector
- BRIA
- SER Health Care
- Exchange
- BRIA NYSE
- SER Nasdaq
- Market Cap
- BRIA 47.1M
- SER 56.5M
- IPO Year
- BRIA 2024
- SER 2018
- Fundamental
- Price
- BRIA $2.47
- SER $5.85
- Analyst Decision
- BRIA
- SER Strong Buy
- Analyst Count
- BRIA 0
- SER 1
- Target Price
- BRIA N/A
- SER $11.00
- AVG Volume (30 Days)
- BRIA 8.7K
- SER 17.8K
- Earning Date
- BRIA 08-15-2025
- SER 08-08-2025
- Dividend Yield
- BRIA N/A
- SER N/A
- EPS Growth
- BRIA N/A
- SER N/A
- EPS
- BRIA 92.24
- SER N/A
- Revenue
- BRIA $59,695,825.00
- SER $51,000.00
- Revenue This Year
- BRIA N/A
- SER N/A
- Revenue Next Year
- BRIA N/A
- SER N/A
- P/E Ratio
- BRIA $0.03
- SER N/A
- Revenue Growth
- BRIA 8.03
- SER N/A
- 52 Week Low
- BRIA $1.78
- SER $3.81
- 52 Week High
- BRIA $4.38
- SER $12.69
- Technical
- Relative Strength Index (RSI)
- BRIA N/A
- SER 50.74
- Support Level
- BRIA N/A
- SER $5.78
- Resistance Level
- BRIA N/A
- SER $6.30
- Average True Range (ATR)
- BRIA 0.00
- SER 0.35
- MACD
- BRIA 0.00
- SER -0.03
- Stochastic Oscillator
- BRIA 0.00
- SER 36.74
About BRIA BRILLIA INC
BrilliA Inc is engaged in business of sales and marketing of lingerie's products including bra, panty and body suit, mainly serving the American, European and other markets.
About SER Serina Therapeutics Inc.
Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers. The Company has one reportable segment relating to the research and development of its POZ platform.